- Home
- S vs PCVX Comparison
S vs PCVX Comparison
Compare S & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | PCVX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.0B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | S | PCVX |
|---|---|---|
| Price | $25.65 | $60.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 34 | 11 |
| Target Price | $24.92 | ★ $117.30 |
| AVG Volume (30 Days) | ★ 9.8M | 3.4M |
| Earning Date | 12-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,001,278,000.00 | N/A |
| Revenue This Year | $20.31 | N/A |
| Revenue Next Year | $17.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.89 | N/A |
| 52 Week Low | $11.81 | $39.87 |
| 52 Week High | $26.50 | $90.75 |
Technical Indicators
Market Signals| Indicator | S | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 44.94 |
| Support Level | $21.44 | $58.51 |
| Resistance Level | $26.50 | $63.08 |
| Average True Range (ATR) | 1.23 | 3.51 |
| MACD | 0.06 | -0.92 |
| Stochastic Oscillator | 84.59 | 6.93 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.